Printer Friendly

THERAPEUTIC DISCOVERY ANNOUNCES NEW BOARD MEMBERS

 PALO ALTO, Calif., June 8 /PRNewswire/ -- Gary Neil, Ph.D., president and chief executive officer of Therapeutic Discovery Corp. (TDC)(NASDAQ-NMS: TDCZ), today announced the appointment of Allen Phipps and Paul Lairson, M.D., to the TDC Board of Directors. TDC was recently formed by ALZA Corp. (NYSE: AZA) for the purpose of selecting and funding the development of new human pharmaceutical products combining ALZA's proprietary drug delivery systems with existing drug compounds, and commercializing such products. ALZA has an option to license any products developed by TDC, providing ALZA with a potential pipeline of products for worldwide commercialization. ALZA also has an option to purchase all of the outstanding shares of TDC Common Stock.
 Phipps, who will serve as chairman of the TDC Board of Directors, is currently managing director of Business Engineering Inc., a new business development and consulting firm. Phipps also maintains an independent management consulting practice in corporate strategy development and organizational effectiveness. He has also served as vice president/director of The Boston Consulting Group, president and chief executive officer of Sellectek Inc., executive vice president of Consulting Services at Regis McKenna Inc. and president and chief executive officer of Bio-Electro Systems Inc.
 Lairson is a private consultant working with medical groups, large employers and hospitals on issues related to managed care. He currently serves on a Kaiser Permanente Medical Care Program task force on health care reform. Most recently, Lairson served as the director of the Permanente Medical Groups Interregional Services for nine years. Lairson has also served in many capacities for Kaiser Permanente, including medical adviser to the Kaiser Permanente Advisory Services and director of The Permanente Medical Association of Texas. He has served on the faculty of the Georgetown University Medical School and on numerous state and national committees and boards.
 Lairson and Phipps will join Neil on the TDC Board of Directors. Neil was previously with American Home Products as executive vice president of American Home Products' subsidiary Wyeth-Ayerst Research, where he had been responsible for Wyeth-Ayerst's worldwide research and development organization.
 As described in the information statement concerning TDC, distributed to ALZA stockholders, all of the initial members of the TDC Board of Directors, who are employees of ALZA, have resigned in connection with the appointment of the new directors. Units, consisting of one share of TDC Common Stock and one warrant to purchase one-eighth of one share of ALZA Common Stock, are currently trading on a when-issued basis on the NASDAQ National Market System under the trading symbol "TDCZV" until June 14, 1993, when the Units will begin trading regular way under the symbol "TDCAZ"
 -0- 6/8/93
 /CONTACT: Michele Mandell of TDC, 415-496-8200/
 (TDCZV AZA)


CO: ALZA Corp.; Therapeutic Design Corp. ST: California IN: MTC SU: PER

SG-GT -- SJ006 -- 6631 06/08/93 14:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:469
Previous Article:GENPHARM RESEARCHERS TRANSFER HUMAN ANTIBODY GENE TO TRANSGENIC MICE
Next Article:MERGER COMPLETE FOR VILLA RICA BANCORP AND FIRST NATIONAL BANCORP
Topics:


Related Articles
THERAPEUTIC DISCOVERY CORP. APPOINTS DIRECTOR
THERAPEUTIC DISCOVERY APPOINTS NEW BOARD MEMBER
WAHL APPOINTED VICE PRESIDENT OF CLINICAL RESEARCH AT AFFYMAX PHARMACEUTICALS
IRWIN LERNER NOMINATED TO AFFYMAX BOARD OF DIRECTORS
ICAgen Appoints Dr. Charles A. Sanders to Board of Directors; Former Chairman and CEO of Glaxo Joins ICAgen Board
Francis P. Tally, M.D., Appointed to Therion Biologics Board of Directors
Alnylam Pharmaceuticals Appoints Dr. Thomas Ulich as Head of R&D.
Sagres Discovery Names Key Oncology and Drug Development Experts To Scientific Advisory Board; Distinguished Board Members to Guide Company's Drug...
Lexicon Genetics Elects Frank Palantoni to Board of Directors.
Anaptys Biosciences Names Former Xoma Executive as Chairman and CEO.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters